FDA Drug Recall: LICEOUT Liquid Lice Treatment for Manufacturing Violations
Neogen Corporation voluntarily recalled 5,328 sachets of LICEOUT lice treatment due to manufacturing practice violations. The product was distributed to Bob Barker Company for institutional facilities.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA classified this as a Class II recall based on manufacturing practice violations. No illnesses or injuries have been reported in relation to this product.
Plain-English summary
Neogen Corporation has voluntarily recalled 5,328 sachets of LICEOUT Liquid Lice Treatment (NDC 53427-124-01) due to manufacturing practice violations. The recalled lot is LO09530 with an expiration date of September 5, 2025.
The recall stems from violations of Current Good Manufacturing Practice (CGMP) requirements. Neogen Corporation identified these compliance issues and initiated the recall on October 8, 2024.
The product was sold directly to Bob Barker Company, Inc., which distributes supplies to institutional facilities including correctional institutions. Those with this product should contact their healthcare provider or facility administrator for guidance.
The recalled product
- Product
- LICEOUT, Liquid Lice Treatment for Human Use, Contents: 1 FL. OZ. (29.6 mL) per sachet, Distributed By: Bob Barker Company, Inc., 7925 Purfoy Road, Fuquay-Varina, NC 27526. NDC: 53427-124-01
- Manufacturer
- Neogen Corporation
- Category
- Drug — Lice Treatment
- Hazard
- cgmp-violation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot LO09530
- Exp 9/5/2025
Distribution
Distribution scope not specified by the agency.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereErythromycin Tablets Recalled for Impurity Above Acceptable Limits
FDA (Drugs) · 2026-05-27
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27